GlaxoSmithKline plc (GSK) Receives GBX 1,597.67 Consensus PT from Brokerages
Shares of GlaxoSmithKline plc (LON:GSK) have received a consensus rating of “Hold” from the twenty ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is GBX 1,597.67 ($20.88).
Several research analysts have commented on GSK shares. Goldman Sachs Group set a GBX 1,900 ($24.83) price target on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Monday, July 23rd. UBS Group restated a “buy” rating and set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a research report on Monday, July 23rd. Barclays set a GBX 1,750 ($22.87) price objective on GlaxoSmithKline and gave the company a “buy” rating in a research report on Monday, July 23rd. Liberum Capital restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, July 23rd. Finally, HSBC set a GBX 2,000 ($26.13) price objective on GlaxoSmithKline and gave the company a “buy” rating in a research report on Friday, July 27th.
Shares of LON GSK opened at GBX 1,583 ($20.68) on Friday. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: What is a Market Correction?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.